Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and bioequivalence of MYL-1401H vs G-Lasta in Japanese healthy adults
jRCT2071210138Phase 1Completed
- Sponsor
- Mylan
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of pegfilgrastim in chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) (2 arms), sponsored by Mylan. Started Mar 2022; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)febrile neutropenia (FN)
Beyond the preview
Go deeper on jRCT2071210138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210138.